By: IPP Bureau
Last updated : October 01, 2025 8:32 am
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Novartis announced the launch of a new direct-to-patient (DTP) platform in the United States, effective November 1, 2025. The platform will provide cash-paying patients prescribed Cosentyx (secukinumab) with access to the medicine at a 55 per cent discount off the list price.
Cosentyx, the company’s top-selling product in the U.S., is a biologic therapy approved by the FDA for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa, and psoriatic arthritis. Since its launch in 2015, Cosentyx has been prescribed to more than 1.8 million patients worldwide and is supported by over 17 years of clinical research.
“Breakthrough innovation is what drives us at Novartis—whether in scientific research, medicine development, or the ways we deliver our therapies to patients,” said Victor Bultó, President, Novartis US. “We recognize the need for new approaches to reach patients more directly by removing barriers in the system. The launch of this platform is an important first step in offering our net prices more directly to patients and working toward a healthcare system that better serves Americans.”
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers. This initiative serves as a proof-of-concept for a direct-selling model in specialty medicines, designed to complement insurance coverage and improve affordability.
Building on this foundation, Novartis plans to expand the DTP model to additional products in its portfolio, where appropriate. The company is also exploring a direct-to-employer model to offer Cosentyx and potentially other medicines directly to large employers, further enhancing access and affordability for U.S. patients.